Ignite Creation Date:
2024-05-06 @ 3:33 AM
Last Modification Date:
2024-10-26 @ 11:35 AM
Study NCT ID:
NCT02317445
Status:
COMPLETED
Last Update Posted:
2014-12-16
First Post:
2014-11-13
Brief Title:
Relationship of Helicobacter Pylori Eradication Therapy and Long-term Outcome in Acute Coronary Syndrome
Sponsor:
Capital Medical University
Organization:
Capital Medical University
Study Overview
Official Title:
Beijing Tiantan HospitalCapital Medical University
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objective To investigate the relationship between Helicobacter pylori Hp infection and the prognosis of acute coronary syndrome ACS in a Chinese population and to explore the significance of Hp eradication therapy in preventing major adverse cardiac events MACE and upper gastrointestinal bleeding UGIB in patients on dual antiplatelet treatment Methods To analyze 472 ACS patients with drug-eluting stent DES implantation from January 1 2008 to December 31 2010 in the department of cardiology at Beijing Mentougou District Hospital Patients were divided into three groups Group 1 the Hp-negative patients Hp- Group 2 the Hp-positive patients with eradication therapy Hp Therapy and Group 3 the Hp-positive patients without eradication therapy Hp No Therapy All patients took 13C urea breath test high sensitive C-reactive protein hs-CRPhomocysteine HCY and other biochemical indicators The investigators explored the correlations of Hp eradication therapy with MACE including recurrent myocardial infarction revascularization and death and UGIB after 3 to 5 years of follow-up using survival analysis
Detailed Description:
This study is a single-center and random analysis The consecutive hospitalized patients with ACS at Beijing Mentougou District Hospital from January 1 2008 to December 31 2010 were enrolled Figure 1 is a flow diagram of the trial There were 259 males 549 and 213 females 451 with an average age of 611 110 years Patients history physical examination and laboratory results were recorded All patients were divided into the Hp-negative group Hp- group 1 and the Hp-positive group Hp The Hp group were randomly divided into two groups Group 2 the Hp with eradication therapy Hp Therapy and Group 3 the Hp without eradication therapy HpNo Therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None